Clinical trials: Epirubicin
Breast Cancer
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, epirubicin, cyclophosphamide, and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087178
- Testing
- cyclophosphamide, adriamycin, epirubicin
- Where
- 606 sites in United States, Canada and 1 more
- Volunteers
- 2,722 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
This study aims to evaluate the efficacy and safety of pyrotinib in combination with nab-paclitaxel or trastuzumab with nab-paclitaxel as neoadjuvant therapy in early stage or locally advanced HER2-positive breast cancer.
- Trial name
- NCT04066790
- Testing
- Pyrotinib, nab-Paclitaxel, Trastuzumab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Hepatocellular Carcinoma
TACE With Dicycloplatin(TP21) in Unresectable HCC
To evaluate the effectiveness and safety of TP21 injection for TACE in treatment of hepatocellular carcinoma: 1. Primary efficacy endpoint: progression-free survival (PFS), which will be assessed by the Independent Review…
- Trial name
- NCT05472896
- Testing
- cTACE, Dicycloplatin (TP21), Epirubicin
- Where
- China
- Volunteers
- 332 people
- Sponsor
- Gao-jun Teng
Hepatocellular Carcinoma
Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection
The purpose of this study is to assess the efficacy and safety of Apatinib Mesylate combined with PD-1 antibody SHR-1210 in HCC patients with high risk of disease recurrence contained microsatellite lesions, microvascular…
- Trial name
- NCT03839550
- Testing
- Apatinib Mesylate +SHR-1210, Hepatic Arterial Infusion(HAI)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Stomach Neoplasms, Gastric Cancer
Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer
Scirrhous gastric cancer, also known as linitis plastic or Borrmann type 4, is an aggressive tumor with an extremely poor prognosis. Aggressive surgical procedures and adjuvant chemotherapies have not improved the survival rate.
- Trial name
- NCT-B4 (NCT02949258)
- Testing
- oxaliplatin, etoposide, epirubicin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jinling Hospital, China
Breast Cancer
Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
To investigate the efficacy of albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer.
- Trial name
- NCT04136782
- Testing
- Albumin-bound paclitaxel combined with carboplatin, Epirubicin combined with docetaxel
- Where
- 7 sites in China
- Volunteers
- 110 people
- Sponsor
- Shengjing Hospital
Osteosarcoma, Soft Tissue Sarcoma (STS)
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on bone and soft tissue sarcoma.
- Trial name
- NCT06699576
- Testing
- HS-20093, Anlotinib, Epirubicin
- Volunteers
- 448 people
- Sponsor
- Hansoh BioMedical R&D Company
Triple -Negative Breast Cancer
Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
This is a multicenter, open-label, dose-escalation trial using a backfill Bayesian optimal interval (BF-BOIN) design to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) for paclitaxel oral…
- Trial name
- GBCF003 (NCT07739485)
- Testing
- Epirubicin and cyclophosphamide followed by paclitaxel oral solution
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Liu Shu
DLBCL - Diffuse Large B Cell Lymphoma, TP53
AZA Combined With RCHOP in P53-mutated DLBCL.
To evaluate the efficacy and adverse effects of Azacitidine in combination with R-CHOP (ARCHOP) for the treatment of TP53-mutated previously untreated Diffuse large B-cell lymphoma
- Trial name
- NCT06158399
- Testing
- Azacitidine in combination with R-CHOP
- Where
- China
- Volunteers
- 52 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Triple Negative Breast Cancer
MicroRNA Profiles in Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) is an aggressive disease with higher proportion of Blacks affected and in younger age groups.
- Trial name
- TARMAC (NCT04771871)
- Testing
- Epirubicin, Cyclophosphamide, Paclitaxel
- Where
- 4 sites in Nigeria
- Volunteers
- 42 people
- Sponsor
- University College Hospital, Ibadan
Breast Cancer
Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer
The study hypothesis is that the new drug EndoTAG-1 will improve tumor volume reduction as measured by Magnetic Resonance Imaging when added to a standard chemotherapy regimen of weekly paclitaxel.
- Trial name
- EndoTAG-1 (NCT01537536)
- Testing
- EndoTAG-1
- Where
- Belgium
- Volunteers
- 18 people
- Sponsor
- Jules Bordet Institute
HER2-Positive Breast Cancer
TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer
Both TCH (docetaxel/carboplatin/trastuzumab) and EC followed by TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) regimens as Neoadjuvant Treatment for HER2-Positive Breast Cancer have been recommended by NCCN…
- Trial name
- neoCARH (NCT03140553)
- Testing
- TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Guangdong Provincial People's Hospital
Breast Cancer
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
This study will evaluate the effect of bevacizumab in combination with chemotherapy or endocrine therapy, as preoperative treatment, in participants with HER2 negative breast cancer.
- Trial name
- NCT00773695
- Testing
- Aromatase Inhibitor, Bevacizumab, Epirubicine
- Where
- 3 sites in Norway
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
TNBC
A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer
Camrelizumab + Chemoradiotherapy for Early TNBC Sponsor/Leading Center: Tianjin Medical University Cancer Institute and Hospital Study Type: Single-arm, single-center, Phase Ⅱ clinical study Planned Enrollment: 43 patients…
- Trial name
- NCT07491822
- Testing
- treatment group
- Volunteers
- 43 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer
Anthracycline-containing regimens are recommended as adjuvant treatment for women with node positive breast cancer. In at least three large randomized clinical trials the addition or sequential administration of a taxane…
- Trial name
- NCT00431080
- Testing
- Docetaxel, Paclitaxel, Epirubicin
- Where
- 10 sites in Greece
- Volunteers
- 478 people
- Sponsor
- Hellenic Oncology Research Group
Gastric Cancer, Adenocarcinoma of the Gastroesophageal Junction
Perioperative Chemo and Pembrolizumab in Gastric Cancer
This is a non-randomized, multi-site, open-label trial of pembrolizumab and chemotherapy in subjects with gastric or gastroesophageal (GE) junction adenocarcinoma.
- Trial name
- NCT02918162
- Testing
- Pembrolizumab, Standard of care chemotherapy regimen
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Gulam Manji
Neoplasms, Breast
Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
This study will examine safety and efficacy of Lapatinib in combination with a standard neoadjuvant chemotherapy including 5FU, Epirubicin, Cyclophosphamide and Paclitaxel.
- Trial name
- NCT00524303
- Testing
- Trastuzumab, Paclitaxel, FEC75
- Where
- 23 sites in United States
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- TACT2 (NCT00301925)
- Testing
- pegfilgrastim, capecitabine, cyclophosphamide
- Where
- 152 sites in United Kingdom
- Volunteers
- 4,400 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Esophageal Neoplasms
Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial
The purpose of this study is to compare the results of preoperative chemotherapy and radiation followed by surgery to surgery followed by postoperative chemotherapy and radiation for esophageal cancer.
- Trial name
- QUINTETT (NCT00907543)
- Testing
- Preoperative treatment of chemotherapy and radiation, Postoperative treatment of chemotherapy and radiation
- Where
- Canada
- Volunteers
- 96 people
- Sponsor
- Richard Malthaner
Small Cell Lung Cancer Extensive Stage
SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer
Patients with extensive disease SCLC after failure of first-line treatment were enrolled with SHR-1210 and epirubicin for 3 cycles to evaluate initial efficacy
- Trial name
- NCT03755115
- Testing
- Epirubicin plus SHR1210
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital